A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.
| Autor: | Yamamoto N; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Tsurutani Y; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Katsuragawa S; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Kubo H; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Sunouchi T; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Hirose R; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Hoshino Y; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Ichikawa M; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Takiguchi T; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Yukawa H; Department of Medical Oncology, Yokohama Rosai Hospital, Japan., Arioka H; Department of Medical Oncology, Yokohama Rosai Hospital, Japan., Saitou J; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Nishikawa T; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Internal medicine (Tokyo, Japan) [Intern Med] 2019 Oct 01; Vol. 58 (19), pp. 2825-2830. Date of Electronic Publication: 2019 Jun 27. |
| DOI: | 10.2169/internalmedicine.2780-19 |
| Abstrakt: | A 77-year-old-man with renal cell carcinoma who was undergoing nivolumab treatment visited our department due to hyperglycemia; his plasma glucose level was 379 mg/dL. Although his serum C-peptide immunoreactivity (CPR) level was preserved (5.92 ng/mL), we suspected an onset of fulminant type 1 diabetes mellitus (FT1DM) and immediately started insulin therapy. His CPR levels gradually decreased and were depleted within 1 week. We later discovered that the patient's casual CPR level had been abnormally high (11.78 ng/mL) 2 weeks before his admission. Hence, the possibility of FT1DM in hyperglycemic patients undergoing nivolumab treatment should not be excluded, even with a preserved CPR level. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|